Cancer Chemotherapy and Pharmacology

Involvement of cytochrome P450 enzymes in inflammation and cancer: a review

Maria Carolina Stipp, Alexandra Acco

The use of zebrafish model in prostate cancer therapeutic development and discovery

Haneen Amawi, Alaa A. A. Aljabali, Sai H. S. Boddu, Sadam Amawi, Mohammad A. Obeid, Charles R. Ashby Jr., Amit K. Tiwari

Irinotecan-induced intestinal mucositis in mice: a histopathological study

Thaise Boeing, Marcelo Biondaro Gois, Priscila de Souza, Lincon Bordignon Somensi, Débora de Mello Gonçales Sant´Ana, Luisa Mota da Silva

A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors

Haeseong Park, Kerry Williams, Nikolaos A. Trikalinos, Sarah Larson, Benjamin Tan, Saiama Waqar, Rama Suresh, Daniel Morgensztern, Brian A. Van Tine, Ramaswamy Govindan, Jingqin Luo, A. Craig Lockhart, Andrea Wang-Gillam

A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects

X. Zhu, Y. Ding, Y. Yu, M. Wang, W. Zhou, J. Wang, X. Zhu, H. Zhang, M. Wang, K. Chai, X. Zhang, A. Luk, W. Jiang, S. Liu, Q. Zhang

Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed

Madusha Meemanage, Lindsay C. Spender, Diane Collinson, Joanna Iannetta, Pranavi Challapalli, Julie Turbitt, Caroline Clark, Mark Baxter, Graeme Murray, Shaun Walsh, Zofia Miedzybrodzka, Russell D. Petty

Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia

Abrar Al-Sheikh, Al-Motassem Yousef, Daniah Alshamaseen, Rand Farhad

A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers

Rui Chen, Hongyun Wang, Wen Zhong, Salvatore Chessari, Corinna Lanzarotti, Alberto Bernareggi, Pei Hu

FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study

Kumiko Umemoto, Hideaki Takahashi, Chigusa Morizane, Ikuhiro Yamada, Satoshi Shimizu, Kazuhiko Shioji, Yukio Yoshida, Masayo Motoya, Nobumasa Mizuno, Yasushi Kojima, Takeshi Terashima, Kazuhiro Uesugi, Makoto Ueno, Junji Furuse, Tetsuo Akimoto, Masafumi Ikeda

FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway

Ya-Kun Liu, Ya-Jing Jia, Shi-Hao Liu, Jing Ma

Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer

Shuang Liu, Shoujing Zhao, Yang Dong, Tingting Wang, Xiaojia Niu, Lijing Zhao, Guan Wang

Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation

Chuan-Kun Shan, Yi-Bo Du, Xiao-Tian Zhai, Yue-Xuan Wang, Yi Li, Jian-Hua Gong, Zhi-Juan Ge, Xiu-Jun Liu, Yong-Su Zhen

BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series

Sabeeh-ur-Rehman Butt, Alberto Mejias, Cristina Morelli, Gonzalo Torga, Marlene Happe, Anna Patrikidou, Hendrik-Tobias Arkenau

Acknowledgement of reviewers 2020